Advances in glucocorticoid therapy

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages 317-349

  Baxter, John D ^a,b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CORTICOTROPIN; GLUCOCORTICOID;

CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFECTION; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADRENOCORTICOTROPIC HORMONE; DRUG COMBINATIONS; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFECTION; OSTEOPOROSIS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0033629479     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. Magiakou M, Chrousos G: Corticosteroid therapy, nonendocrine disease, and corticosteroid withdrawal. Curr Ther Endocrinol Metab 6:138-142, 1997.
2. Tyrrell JB. Glucocorticoid therapy, in Felig P, Baxter J, Frohman L (eds). Endocrinology and Metabolism. New York, McGraw-Hill, 1995, pp 855-882.
3. Baxter J: The effects of glucocorticoid therapy. Hosp Pract 27:111-134, 1992.
4. Baxter J: Cortisone and the adrenal cortex. Trans Assoc Amer Phys 99:167-183, 1986.
5. Miller W, Tyrrell J: The adrenal cortex, in Felig P, Baxter J, Frohman L (eds): Endocrinology and Metabolism. New York, McGraw-Hill, 1995, pp 555-711.
6. Findling J, Aron D, Tyrrell J: Glucocorticoids and adrenal androgen, in Greenspan F, Strewler GJ (eds): Basic and Clinical Endocrinology. Stamford, Appleton and Lange, 1997, pp 317-358.
7. Baxter J, PH F: Tissue effects of glucocorticoids. Am J Med 53:573-589, 1972.
8. Baxter J: Minimizing the side effects of glucocorticoid therapy, in Advances in Internal Medicine, vol 35. St Louis, Mosby, 1990, pp 173-194.
9. Baxter J, Rousseau G: Glucocorticoid hormone action: An overview, in Baxter J, Rousseau G (eds): Glucocorticoid Hormone Action, vol 12. Heidelberg, Springer Verlag, 1979, pp 1-24.
10. Brack A, Rittner H, Younge B, et al: Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 99:2842-2850, 1997.
11. Leung D, Szefler S: New insights into steroid resistant asthma. Pediatr Allergy Immunol 9:3-12, 1998.
12. Segal B, Sneller M: Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 23:219-237, 1997.
13. Ribeiro R, Kushner P, Baxter J: The nuclear hormone receptor gene superfamily. Annu Rev Med 46:425-435, 1995.
14. Baxter J: General concepts of endocrinology, in Greenspan F, Strewler G (eds): Basic and Clinical Endocrinology Stamford, Appleton & Lange, 1994, pp 1-38.
15. DeRijk R, Sternberg E: Corticosteroid resistance and disease. Ann Med 29:79-82, 1997.
16. Karl M, Lamberts S, Koper J, et al: Cushing's disease preceded by generalized glucocorticoid resistance: Clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assoc Am Physicians 108:296-307, 1996.
17. Stewart P: Cortisol, hypertension and obesity: The role of 11 beta-hydroxysteroid dehydrogenase. J R Coll Physicians Lond 32:154-159, 1998.
18. Baxter J, Perloff D, Hsueh W, et al: The endocrinology of hypertension, in Felig P, Baxter J, Frohman L (eds): Endocrinology and Metabolism. New York, McGraw-Hill, 1995, pp 749-853.
19. Bracken M: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277:1597-1604, 1997.
20. Young W, Kume-Kick J, Constantini S: Glucocorticoid therapy of spinal cord injury. Ann N Y Acad Sci 743(4):241-265, 1996.
21. van Uum S, Hermus A, Smits P, et al: The role of 11B-hydroxysteroid dehydrogenase in the pathogenesis of hypertension. Cardiovasc Res 38:16-24, 1998.
22. Schäfer-Korting M, Schmid M, Korting H: Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drugs 50:854-872, 1995.
23. Robertson D, Maibach H: Topical glucocorticoids, in Schleimer RP, Oronsky AH, (eds): Anti-Inflammatory Steroid Action. San Diego, Academic Press, 1989, pp 494-524.
24. Korting H, Kerscher M, Schhäfer-Korting M: Topical glucocorticoids with improved benefit/risk ratio: Do they exist? J Am Acad Dermatol 27:87-92, 1992.
25. Prakash A, Benfield P: Topical mometasone: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Mayo Clin Proc 72:1141-1144, 1997.
26. Barnes N: Relative safety and efficacy of inhaled corticosteroids. J Allergy Clin Immunol 101:S460-464, 1998.
27. British Thoracic Society. Guidelines for the management of asthma in adults, I: Chronic persistent asthma. BMJ 301:651-653, 1990.
28. International consensus report on diagnosis and management of asthma. Clin Exp Allergy 22(suppl 1):1-71, 1992.
29. National Heart, Lung and Blood Institute international consensus report on diagnosis and treatment of asthma. Eur Respir J 5:601-641, 1992.
30. Boushey H: Effects of inhaled corticosteroids on the consequences of asthma. J Allergy Clin Immunol 102:S5-S16, 1998.
31. Lemanske R, Busse W: Asthma. JAMA 278:1855-1873, 1997.
32. Boushey H: Treatment of chronic severe asthma. West J Med 167:359-360, 1997.
33. Dluhy R: Clinical relevance of inhaled corticosteroids and HPA axis suppression. J Allergy Clin Immunol 101:S447-450, 1998.
34. Braverman D, Lachmann E, Nagler W: Avascular necrosis of bilateral knees secondary of corticosteroid enemas. Arch Phys Med Rehabil 79:449-452, 1998.
35. Thiesen A, Thomson A: Review article: Older systemic and newer topical glucocorticosteroids and the gastrointestinal tract. Drug Saf 14:375-385, 1996.
36. Friend D: Review article: Issues in oral administration of locally acting glucocorticoids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 12:591-603, 1998.
37. Ravaud P, Moulinier L, Giraudeau B, et al: Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: Results of a multicenter, randomized controlled trial. Arthritis Rheum 42:475-482, 1999.
38. Jones A, Regan M, Ledingham J, et al: Importance of placement of intra-articular steroid injections. BMJ 307:1329-1330, 1993.
39. Lazarevic M, Skosey J, Djordevic-Denic G, et al: Reduction of cortisol levels after single intra-articular and intramuscular steroid injection, Am J Med 99:370-373, 1995.
40. Bollaert P-E, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645-650, 1998.
41. Christy N: Iatrogenic Cushing's syndrome, in Christy N (ed): The Human Adrenal Cortex. New York, Harper and Row, 1971, pp 395.
42. Austin HA, Boumpas DT: Treatment of lupus nephritis. Semin Nephrol 16:527-535, 1996.
43. Pauwels R, Lofdahl C-G, Postma D, et al: Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337:1405-1411, 1997.
44. Evans D, Taylor D, Zetterstrom O, et al: A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337:1412-1418, 1997.
45. Keenan G: Management of complications of glucocorticoid therapy. Clin Chest Med 18:507-517, 1997.
46. Jain R, Lipsky P: Treatment of rheumatoid arthritis. Med Clin North Am 81:57-84, 1997.
47. Boers M, AC V, Markusse H, et al: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309-318, 1997.
48. Ratcliffe P, Dudley C, Higgins R, et al: Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 348:643-648, 1996.
49. Frampton J, Faulds D: Cyclosporin: A pharmacoeconomic evaluation of its use in renal transplantation. Pharmacoeconomics 4(5):366-395, 1993.
50. Calabrese LH: Therapy of systemic vasculitis. Neural Clin 15:973, 1997.
51. Cannistra S: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207, 1997.
52. Cohen M, Conn D: Benefits of low-dose corticosteroids in rheumatoid arthritis. Bull Rheum Dis 46:4-7, 1997.
53. Stuck A, Minder C, Frey F: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954-963, 1989.
54. Kirwan J: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333:142-146, 1995.
55. Youssef P, Haynes D, Triantafillou S, et al: Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 40:1400-1408, 1997.
56. White K, Driscol M, Rothe M, et al: Severe adverse cardiovascular effects of pulse steroid therapy: Is continuous cardiac monitoring necessary? Mediators Inflamm 7:183-193, 1998.
57. Smith M, Pawar R, Carey J, et al: Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med 97:145-151, 1994.
58. Allen D: Influence of inhaled corticosteroids on growth: A pediatric endocrinologist's perspective. Pediatrics 87:123-129, 1998.
59. Cumming R, Mitchell P, Leeder, S: Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 337:8-14, 1997.
60. Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 101:S434-439, 1998.
61. Derendorf H, Hochhaus G, Meibohm B, et al: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:S440-446, 1998.
62. Drazen J, Israel E, O'Byrne P: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206, 1999.
63. Sasaki E: Corticosteroid sensitivity and cross-sensitivity. A review of 18 cases 1967-1988. Contact Dermatitis 23:306-315, 1990.
64. Lutz M, El-Azhary R: Allergic contact dermatitis due to topical application of corticosteroids: Review and clinical implications. Mayo Clin Proc 72:1141-1144, 1997.
65. Awan A, Harmenberg J, Flink O, et al: Combinations of antiviral and anti-inflammatory preparations for the topical treatment of herpes simplex virus assessed using a murine zosteriform infection model. J Immunol 161:6861-6870, 1998.
66. Abeck D, Mempel M: Staphylococcus aureus colonization in atophic dermatitis and its therapeutic implications. Horm Metab Res 30:726-729, 1998.
67. Bollow M, Braun J, Taupitz M, et al: CT-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with spondyloarthropathy: Indication and follow-up with contrast-enhanced MRI. J Comput Assist Tomogr 20:512-521, 1996.
68. Baxter J, Tyrell J: Evaluation of the hypothalamic-pituitary-adrenal axis: Importance in steroid therapy, AIDS, and other stress syndromes, in Schrier R, Abboud F, Baxter J, et al (eds): Advances in Internal Medicine, vol 33. St. Louis, Mosby, 1994.
69. Sarna S, Hoppu K, Neuvonen P, et al: Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. J Clin Endocrinol Metab 82:75-77, 1997.
70. Kountz D, Clark C: Safely withdrawing patients from chronic glucocorticoid therapy. Am Fam Physician 55:521-525, 1997.
71. Campion E: Cataracts and inhaled corticosteroids. N Engl J Med 337:46-48, 1997.
72. Thaler L, Blevins L: The low dose 1-mg adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab 83:2726-2729, 1998.
73. Mayenknecht J, Diederich S, Bahr V, et al: Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 83:1558-1562, 1998.
74. Streeten D, Anderson G, Bonaventura M: The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotron test. J Clin Endocrinol Metab 81:285-290, 1996.
75. Hurel S, Thompson C, Watson M, et al: The short Synacthen and insulin stress tests in the assessment of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol 44:141-146, 1996.
76. Ammari F, Issa B, Millward E, et al: A comparison between short ACTH and insulin stress tests for assessing hypothalamo-pituitary-adrenal function. Clin Endocrinol 44:473-476, 1996.
77. Orme S, Peacey S, Earth J, et al: Comparison of tests of stress-released cortisol secretion in pituitary disease. Clin Endocrinol 45:135-140, 1996.
78. Hockings G, Strakosch C, Jackson R: Secondary adrenocortical insufficiency: Avoiding potentially fatal pitfalls in diagnosis and treatment. Med J Aust 166:400-401, 1997.
79. Streeten D: Shortcomings in the low-dose (1 mg) ACTH test for the diagnosis of ACTH deficiency states (editorial). J Clin Endocrinol Metab 84:835-837, 1999.
80. Salem M, Tainsh R, Bromberg J, et al: Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 219:416-425, 1994.
81. Reid I: Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 137:209-217, 1997.
82. Reid I: Preventing glucocorticoid-induced osteoporosis. N Engl J Med 337:420-421, 1997.
83. Ziegler R, Kasperk C: Glucocorticoid-induced osteoporosis: Prevention and treatment. Steroids 63:344-348, 1998.
84. Lane N, Lukert B: The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 27:465-483, 1998.
85. Reid I: Glucocorticoid effects on bone (editorial). J Clin Endocrinol Metab 83:1860-1862, 1998.
86. Chiodini I, Carnevale V, Torlontano M, et al: Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: Study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 83:1863-1867, 1998.
87. Buckley L, Leib E, Cartularo K, et al: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticoids in patients with rheumatoid arthritis. Ann Intern Med 125:961-968, 1996.
88. Saag K, Emkey R, Schnitzer T, et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299, 1998.
89. Adachi J, Bensen W, Brown J, et al: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387, 1197.
90. 89a. Lane N, Sanchez S, Modin G, et al: Parathyroid hormone treatment can reverse glucocoticoid-induced osteoporosis. J Clin Invest 102:1627-1633, 1998.
91. Wolthers T, Grofte T, Jorgensen J, et al: Growth hormone prevents prednisolone-induced increase in functional hepatic nitrogen clearance in normal man. Neuropsychopharmacology 4:246-257, 1997.
92. Brown D, Lafuse W, Zwilling B: Host resistance to mycobacteria is compromised by activation of the hypothalamic-pituitary-adrenal axis. Ann N Y Acad Sci 840:773-786, 1998.
93. Cai J, Zheng T, Lotz M, et al: Glucocorticoids induce Kaposi's sarcoma cell proliferation through the regulation of transforming growth factor-beta. J Clin Endocrinol Metab 82:75-77, 1997.
94. Quagliarello V, Scheid W: Adjunctive therapy in bacterial meningitis - what makes sense? Infect Agents Dis 1:167-171, 1992.
95. Whitley R, Weiss H, Gnann J Jr, et al: Acyclovir with and without prednisone for the treatment of herpes zoster: A randomized, placebo-controlled trial. Ann Intern Med 125:376-383, 1996.
96. Conn H, Poynard T: Corticosteroid therapy does not induce peptic ulcer. J Intem Med 236:619-632, 1994.
97. Findling J, Raff H: Newer diagnostic techniques and problems in Cushing's disease. Endocnnol Metab Clin North Am 28:191-210, 1999.
98. Norbiato G, Bevilacqua M, Vago T, et al: Glucocorticoids and Th-1, Th-2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS. Clin Exper Rheumatol 15:315-323, 1997.
99. Hirano T, Horigome A, Oka K, et al: Glucocorticoid-resistance in peripheral-blood lymphocytes does not correlate with number of affinity of glucocorticoid-receptors in chronic renal failure patients. Blood 89:1491-1500, 1997.
100. Norblato G, Bevilacqua M, Vago T: Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocnnol Metab 74:608-613, 1992.
101. Lo J, Mulligan K, Tai V, et al: "Buffalo hump" in men with HIV-1 infection. Lancet 351:867-870, 1998.
102. Sellmeyer D, Grunfeld C: Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocrinol Rev 17:518-532, 1996.
103. Karl M, von Wichert G, Kempter E: Nelson's syndrome associated with a somatic frameshift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 81:124-129, 1996.
104. Kaspers G, Pieters R, Klumper E, et al: Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 13:187-201, 1994.
105. Chrousos G, Detera-Wadleigh S, Karl M: Syndromes of glucocorticoid resistance. Ann Intern Med 119:1113-1124, 1993.
106. Szefler S, DYM L: Glucocorticoid-resistant asthma: Pathogenesis and clinical implications for management. Eur Respir J 10:1640-1647, 1997.
107. Lane S, Lee T: Mechanisms of corticosteroid resistance in asthmatic patients. Int Arch Allergy Immunol 113:193-195, 1997.
108. Karin M: New twists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable? Cell 93:487-490, 1998.
109. Mangelsdorf D, Thummel C, Beato M, et al: The nuclear receptor superfamily: The second decade. Cell 83:835-839, 1995.
110. Dumont A, Hehner S, Schmitz M, et al: Cross-talk between steroids and NF-kappa B: What language? Trends Biochem Sci 7:233-235, 1998.